Wesper

Wesper's differentiation is real but narrow, and the market structure around it is unforgiving. Home sleep-apnea testing already has an entrenched winner — the WatchPAT franchise, acquired by Itamar for hundreds of millions and now distributed through ZOLL's clinical machine plus telehealth brands like Lofta — and physicians ordering an HSAT default to the device their workflow, billing, and habit already support. Reimbursement compounds the problem: CPT codes pay for a sleep study, singular, and Wesper's distinctive multi-night longitudinal model has no established payment pathway, pushing it toward cash-pay consumers and wellness channels where unit economics depend on marketing spend the company's roughly $24M lifetime raise cannot sustain — a total that also signals limited institutional appetite since the $9.6M Series A era. The threat from above is existential in shape: Apple Watch and Samsung's FDA-cleared wearables now screen for sleep apnea on hardware tens of millions already wear, and while today they funnel patients toward diagnosis, the trajectory of consumer sensing plus loosening FDA wellness policy points toward the wrist absorbing ever more of the diagnostic journey — leaving dedicated patch systems squeezed between free screening and incumbent-controlled confirmation. Adhesive patches are a recurring consumable cost that cash-pay customers feel, GLP-1 therapy that resolves apnea shrinks each patient's monitoring lifetime, and the dental and coaching channels Wesper courts are fragmented, low-volume buyers. Without a large payer or pharma partnership to institutionalize longitudinal testing — none disclosed — Wesper risks being the most comfortable product in a market whose money flows through other hands.